<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601938</url>
  </required_header>
  <id_info>
    <org_study_id>SNUHEM-SEREAL-12-0001</org_study_id>
    <nct_id>NCT01601938</nct_id>
  </id_info>
  <brief_title>Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients</brief_title>
  <acronym>SEREAL</acronym>
  <official_title>Effects of Selenium Replacement on Prognosis of Severe Sepsis and Septic Shock Patients and Their Initial Serum Selenium Level: a Randomized, Double-blind Placebo Controlled Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gil Joon Suh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosyn</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be performed to determine whether selenium replacement reduces 28-day
      mortality of severe sepsis and septic shock patients, and to investigate whether selenium
      replacement contributes differently to the mortality reduction of the patients according to
      their initial serum selenium level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single center, randomized, double-blind, placebo controlled trial.

      After the diagnosis of severe sepsis and septic shock, enrolled patients will be randomized.
      Then, selenium or placebo will be intravenously administered to them for 7 days. Hemodynamic
      and laboratory data will be recorded for 7 days and additional serum samples will be obtained
      at 0, 24, 72, and 168 hours post-treatment and stored. Mortality will be observed for 28
      days.

      An interim analysis will be conducted by the independent data safety monitoring board.

      Serum selenium levels will be measured from the stored serum samples after the study
      completion.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We failed to obtain study drugs from the company
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All cause mortality occurs within 28 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>3 months</time_frame>
    <description>After 3 months from enrollment, the participant's ICU length of stay will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at hospital discharge</measure>
    <time_frame>3 months</time_frame>
    <description>After 3 months from enrollment, the participant's in hospital mortality will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of the new infection</measure>
    <time_frame>3 months</time_frame>
    <description>After 3 months from enrollment, the development of new infection of the participant during the hospitalization will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum selenium level</measure>
    <time_frame>At 0, 24, 72, 168 hours post-enrollment</time_frame>
    <description>After study completion, serum selenium level will be measured from stored samples. Then, we will investigate whether selenium replacement contributes differently to the mortality reduction of the enrolled patients according to their initial serum selenium level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator days</measure>
    <time_frame>3 months</time_frame>
    <description>After 3 months from enrollment, total numbers of ventilator days of the participant during the hospitalization will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy days</measure>
    <time_frame>3 months</time_frame>
    <description>After 3 months from enrollment, the days of renal replacement therapy of the participant during the hospitalization will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress marker</measure>
    <time_frame>At 0, 24, 72, 168 hours post-enrollment</time_frame>
    <description>After study completion, serum glutathione peroxidase, reduced glutathione, NADPH, and MDA will be measured from stored samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in severity scores</measure>
    <time_frame>7 days</time_frame>
    <description>APACHE II score, SOFA score, and SAPS II will be calculated at 1, 3, 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-month mortality</measure>
    <time_frame>3 months post-enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>At 0, 24, 72, 268 hours post-enrollment</time_frame>
    <description>After study completion, serum cytokines, CRP, and chemokines will be measured from stored samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor days</measure>
    <time_frame>3 months</time_frame>
    <description>Days of dopamine, norepinephrine, dobutamine, vasopressin, and epinephrine will be investigated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sepsis</condition>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mcg of selenium (10mL) daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 10 mL (delivered from biosyn) for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>selenium replacement</intervention_name>
    <description>Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.</description>
    <arm_group_label>Selenium</arm_group_label>
    <other_name>Selenase T pro injectione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 or older

          -  clinical diagnosis of severe sepsis or septic shock

        Exclusion Criteria:

          -  pregnancy or breast feeding

          -  age younger than 18

          -  advanced directive state to withhold treatment

          -  known allergy to selenium

          -  CPR or death within 24 hours after the diagnosis of severe sepsis or septic shock

          -  advanced malignancy without further treatment plan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Joon Suh, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.emergency.or.kr/KoreaMed_KSEM/JournalSearch_index.asp?year=2011&amp;page=684&amp;vol=22&amp;iss=6</url>
    <description>Our preliminary observational study which shows low serum selenium level was associated with poor prognosis of patients with septic shock in Korea.</description>
  </link>
  <reference>
    <citation>Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schüttler J, Gärtner R. Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med. 2007 Jan;35(1):118-26.</citation>
    <PMID>17095947</PMID>
  </reference>
  <reference>
    <citation>Andrews PJ, Avenell A, Noble DW, Campbell MK, Croal BL, Simpson WG, Vale LD, Battison CG, Jenkinson DJ, Cook JA; Scottish Intensive care Glutamine or seleNium Evaluative Trial Trials Group. Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. BMJ. 2011 Mar 17;342:d1542. doi: 10.1136/bmj.d1542.</citation>
    <PMID>21415104</PMID>
  </reference>
  <reference>
    <citation>Forceville X, Laviolle B, Annane D, Vitoux D, Bleichner G, Korach JM, Cantais E, Georges H, Soubirou JL, Combes A, Bellissant E. Effects of high doses of selenium, as sodium selenite, in septic shock: a placebo-controlled, randomized, double-blind, phase II study. Crit Care. 2007;11(4):R73.</citation>
    <PMID>17617901</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Gil Joon Suh</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Shock, Septic</keyword>
  <keyword>Selenium</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

